Pulse Biosciences posted Q2 GAAP net loss of $24.7 million, widening from $19.2 million a year earlier; GAAP loss per share widened to $0.36.
Revenue was $434,000, versus no revenue a year earlier, as it stayed in a controlled commercial launch focused on market development.
GAAP costs and expenses rose to $25.7 million from $20.3 million, driven by higher clinical-program investment and compensation-related spend.
Cash position and clinical progress
Cash and cash equivalents climbed to $101.6 million at June 30 from $68.3 million at March 31, following $46.8 million net ATM proceeds.
NANOPULSE-AF enrollment topped 82 evaluable patients, with completion targeted for early Q4; the company is progressing toward a 2H 2026 CE Mark submission.
PLSE•
